1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Drifting Lower in Friday Trade

01/21/2022 | 01:08pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APPLIED DNA SCIENCES, INC. 0.85% 1.18 Delayed Quote.-70.90%
CUREVAC N.V. -4.88% 17.55 Delayed Quote.-46.23%
MEDTRONIC PLC -0.39% 105.19 Delayed Quote.2.07%
NASDAQ COMP. 2.09% 11500.48 Real-time Quote.-28.00%
All news about CUREVAC N.V.
08:30aCureVac Working With myNEO to Develop New mRNA Immunotherapies
MT
08:11aCureVac Narrows Q1 Pre-Tax Loss as Revenue Rises
MT
07:07aCureVac Announces Financial Results for the First Quarter of 2022 and Provides Busines..
EQ
07:02aCureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vac..
EQ
05/10TRANSCRIPT : CureVac N.V. Presents at Bank of America 2022 Healthcare Conference, May-10-2..
CI
05/09COVID vaccine makers shift focus to boosters
RE
04/28CUREVAC N : Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Prov..
PU
04/28CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/28CureVac Q4 Pre-Tax Loss Narrows, Revenue Rises
MT
04/28TRANSCRIPT : CureVac N.V., Q4 2021 Earnings Call, Apr 28, 2022
CI
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2022 77,0 M 82,6 M 82,6 M
Net income 2022 -376 M -403 M -403 M
Net cash 2022 353 M 379 M 379 M
P/E ratio 2022 -9,01x
Yield 2022 -
Capitalization 3 216 M 3 451 M 3 451 M
EV / Sales 2022 37,2x
EV / Sales 2023 16,0x
Nbr of Employees 824
Free-Float 46,4%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 17,20 €
Average target price 27,55 €
Spread / Average Target 60,2%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean Stéphenne Chairman-Supervisory Board
Igor Splawski Chief Scientific Officer
Malte Greune Chief Operating & Production Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-46.23%3 451
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581